Prosecution Insights
Last updated: April 19, 2026

Exuma Biotech Corp.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17905649 METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTE AGGREGATES SPENCE, JENNIFER SUZANNE 1633 Final Rejection Sep 05, 2022
17684405 METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTES AND/OR RETROVIRAL PARTICLES JOHNSON, ALLISON MARIE 1638 Non-Final OA Mar 01, 2022
17639281 METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES TINSLEY, BRENDAN THOMAS 1634 Non-Final OA Feb 28, 2022
17272631 METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS BURKHART, MICHAEL D 1638 Non-Final OA Mar 01, 2021

Managing Exuma Biotech Corp.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month